Potential treatment for an aggressive form of lung cancer

Researchers have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC). These findings could pave the way for new treatments for patients with mutations in two key genes - KRAS and LKB1. Patients whose tumors contain both of these mutations, known as KL tumors, have poor outcomes and usually do not respond to immunotherapy.

source https://www.sciencedaily.com/releases/2021/01/210105095632.htm